Key terms

About NXTC

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest NXTC news

May 03 8:35am ET Buy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid Financials by TipRanks May 03 6:29am ET Promising Clinical Trial Results Position NextCure’s NC410 as a Potential Game-Changer in Cancer Treatment by TipRanks May 02 4:51pm ET NextCure reports Q1 EPS (61c), consensus (46c) by TipRanks Apr 08 11:45am ET Promising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy Rating by TipRanks Apr 08 7:10am ET NextCure and LCB present data on B7-H4 antibody drug conjugate at AACR by TipRanks Apr 04 7:16am ET NextCure appoints Rakesh Dixit to Scientific Advisory Board by TipRanks Mar 22 6:17am ET Promising Clinical Trial Results for NextCure’s NC410 Bolster Buy Rating by TipRanks Mar 21 2:30pm ET Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC) by TipRanks Mar 21 9:12am ET NextCure Inc to Engage with Investors in Informal Talks by TipRanks Mar 21 9:03am ET NextCure restructures operations, reduces workforce by 37% by TipRanks Mar 21 9:02am ET NextCure announces intention to partner assets by TipRanks Mar 21 9:01am ET NextCure to prioritize NC410 combo, LNCB74 in 2024 by TipRanks Mar 21 8:56am ET NextCure expects resources to fund operations into 2H26 by TipRanks Mar 21 8:56am ET NextCure reports 2023 EPS ($2.25), consensus ($2.28) by TipRanks Mar 05 6:09pm ET NextCure’s treatment of AML granted FDA orphan designation by TipRanks Mar 05 8:26am ET NextCure publishes preclinical data on function of FLRT3 by TipRanks

No recent press releases are available for NXTC

NXTC Financials

1-year income & revenue

Key terms

NXTC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

NXTC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Bruce Garelick was found guilty of insider trading
John Minchillo/AP
Investor found guilty in Trump Media insider trading case
People walk toward an entrance to Disneyland in Anaheim, California on April 24, 2023.
Mario Tama/Getty Images/File
Americans are shopping less but they’re still spending on flights, hotels and Disneyland
Scaffolding and construction netting near an apartment building in New York, US, on Wednesday, Oct. 11, 2023. Monthly fees and expenses for inspections, insurance and climate-friendly upgrades are squeezing residents of the city's many co-op and condo buildings. Photographer: Michael Nagle/Bloomberg
Michael Nagle/Bloomberg/Getty Images
For US renters, the chance of owning a home is going from bad to worse
Close-up detail of the Disney+ app icon on an Apple iPhone 12 Pro smartphone screen, on November 11, 2020. (Photo by Phil Barker/Future Publishing via Getty Images)
Phil Barker/Future Publishing/Getty Images
Disney just had its worst day in a year and a half